Q1 EPS Estimates for Neurocrine Biosciences Cut by Wedbush

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at Wedbush lowered their Q1 2025 earnings per share estimates for Neurocrine Biosciences in a research note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the company will earn $1.44 per share for the quarter, down from their prior forecast of $1.52. Wedbush currently has a “Outperform” rating and a $148.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.93 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.75 EPS, Q3 2025 earnings at $1.85 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $7.23 EPS, FY2026 earnings at $9.89 EPS and FY2029 earnings at $21.23 EPS.

A number of other research firms also recently issued reports on NBIX. Raymond James reiterated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. UBS Group boosted their price target on Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. HC Wainwright reissued a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, BMO Capital Markets dropped their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $165.40.

Neurocrine Biosciences Trading Up 0.8 %

NASDAQ:NBIX opened at $148.73 on Monday. The business’s fifty day moving average price is $134.09 and its 200 day moving average price is $131.27. The firm has a market capitalization of $15.06 billion, a price-to-earnings ratio of 39.87 and a beta of 0.33. Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. abrdn plc grew its holdings in shares of Neurocrine Biosciences by 14.8% in the 4th quarter. abrdn plc now owns 156,574 shares of the company’s stock valued at $21,372,000 after buying an additional 20,150 shares during the period. Trust Point Inc. lifted its holdings in Neurocrine Biosciences by 28.3% during the fourth quarter. Trust Point Inc. now owns 2,483 shares of the company’s stock worth $339,000 after acquiring an additional 548 shares in the last quarter. Jennison Associates LLC grew its stake in Neurocrine Biosciences by 145.1% in the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock valued at $112,025,000 after acquiring an additional 485,894 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Neurocrine Biosciences by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,468 shares of the company’s stock worth $2,930,000 after acquiring an additional 2,047 shares in the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $255,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kyle Gano sold 65,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the transaction, the chief executive officer now owns 135,392 shares in the company, valued at approximately $19,157,968. This trade represents a 32.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,694 shares of company stock worth $9,676,730 over the last 90 days. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.